The updated formula combines the original vaccine with one that targets BA.4 and BA.5 and would be administered as a 30 microgram dose.
The move comes after the FDA told manufacturers to focus updated vaccines on leading omicron subvariants BA.4 and BA.5.
“The agility of the mRNA platform, together with extensive clinical experience with the Pfizer-BioNTech COVID-19 Vaccine, has allowed us to develop, test and manufacture updated, high-quality vaccines that align to circulating strains with unprecedented speed,” Albert Bourla, chairman and chief executive officer of Pfizer, said in a statement.
The companies previously announced data from a trial that showed their BA.1 bivalent booster resulted in a higher immune response against the Omicron variant.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.